Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
981.20B
Market cap981.20B
Price-Earnings ratio
36.68
Price-Earnings ratio36.68
Dividend yield
0.61%
Dividend yield0.61%
Average volume
2.97M
Average volume2.97M
High today
$1,047.25
High today$1,047.25
Low today
$1,015.05
Low today$1,015.05
Open price
$1,024.30
Open price$1,024.30
Volume
2.71M
Volume2.71M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,051.90, giving the company a market capitalization of 981.2B. It carries a P/E multiple of 36.68 and pays a dividend yield of 61.1%.

On 2026-05-22, Eli Lilly(LLY) stock traded between a low of $1,015.05 and a high of $1,047.25. Shares are currently priced at $1,051.90, which is +3.6% above the low and +0.4% below the high.

The Eli Lilly(LLY)'s current trading volume is 2.71M, compared to an average daily volume of 2.97M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

CNBC 13h
Eli Lilly delivered on expectations with obesity shot data, says Mizuho's Jared Holz - CNBC

...

Eli Lilly delivered on expectations with obesity shot data, says Mizuho's Jared Holz - CNBC
Benzinga 16h
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss

The study evaluated retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways, in adults with obesity or overweight and at leas...

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
TipRanks 20h
Eli Lilly’s Next-Generation Weight-Loss Drug Clears Big Hurdle

U.S. pharmaceutical giant Eli Lilly (LLY) says its next-generation weight-loss drug has cleared a late-stage clinical trial in patients who are obese. Start a...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
12.1%
Sell
3%

More LLY News

Barron's 21h
Eli Lilly’s New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial

Biotech and Pharma Eli Lilly’s New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial In this article LLY NVO Eli Lilly shares have fallen around 5% so...

Eli Lilly’s New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial
TipRanks 21h
Eli Lilly’s retatrutide readout strengthens long-term narrative, says Truist

Truist keeps the firm’s Buy rating and a $1,281 price target on Eli Lilly (LLY). The company’s retatrutide Phase 3 clinical trial data in obesity announced this...

Nasdaq 22h
Could Viking Therapeutics Be the Next Eli Lilly?

Key Points Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candid...

Could Viking Therapeutics Be the Next Eli Lilly?
MarketWatch 22h
Lilly’s new experimental shot produced 28% weight loss

A view of the New York Stock Exchange after Eli Lilly’s team rang the opening bell in New York on May 11. (Photo by ANGELA WEISS / AFP via Getty Images) Eli Li...

Lilly’s new experimental shot produced 28% weight loss
The Wall Street Journal 24h
Eli Lilly’s New Weight-Loss Treatment Shows Promising Results

An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial. Mike Blake / Reuters An investigational drug developed b...

Eli Lilly’s New Weight-Loss Treatment Shows Promising Results
CNBC 24h
Eli Lilly says next-generation weight loss drug clears crucial obesity trial

Key Points Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses....

Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Nasdaq 1d
Best Weight Loss Drug Stocks to Buy in 2026

Key Points Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not b...

Best Weight Loss Drug Stocks to Buy in 2026

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.